Drug Discovery

Drug Discovery

Fusogenic Peptides for Delivery of RNAi Therapeutics to Ovarian Cancer


The novel fusogenic peptides improve the delivery of therapeutics for ovarian cancer through their ability to enhance endosomal escape and delivery of bioactive therapeutics. Epithelial ovarian cancer is the 5th leading cancer among women, with a 49% five-year survival rate. Current treatment strategies for ovarian cancer include surgical removal, chemotherapy, and radiation; however, these treatments often prove ineffective or toxic…
Get Started
Ready to Get Started?

Contact our team at CURF

Contact CURF